Infectious causes of cancer

Arbutus to Report Second Quarter 2021 Financial Results and Provide Corporate Update

Medical specialties, Hepadnaviridae, Arbutus Biopharma, ABUS, Infectious causes of cancer, Infectious diseases, Clinical medicine, Hepatitis B
Thursday, July 29, 2021 - 1:00pm

Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 2719108.

Key Points: 
  • Alternatively, you may access a replay of the conference call by calling (855) 859-2056 or (404) 537-3406, and reference conference ID: 2719108.
  • Arbutus Biopharma Corporation is a publicly traded (Nasdaq: ABUS) biopharmaceutical company primarily focused on discovering, developing and commercializing a cure for people with chronic hepatitis B virus (HBV) infection.
  • The Company is advancing multiple product candidates with distinct mechanisms of action that it believes have the potential to provide a new curative regimen for chronic HBV infection.
  • Arbutus has also initiated a drug discovery and development effort for treating coronaviruses (including COVID-19).

Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review H2, 2021 - ResearchAndMarkets.com

Health, Clinical trials, Health, Infectious causes of cancer, Clinical medicine, Gynaecological cancer, Papillomavirus, Vaccines, Intraepithelial neoplasia, Lesion, Cervical intraepithelial neoplasia, Cin, Clinical trial, HspE7
Thursday, July 29, 2021 - 12:31pm

The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • "Cervical Intraepithelial Neoplasia (CIN) - Global Clinical Trials Review, H2, 2021" provides an overview of the Cervical Intraepithelial Neoplasia (CIN) Clinical trials scenario.
  • This report provides top line data relating to the clinical trials on Cervical Intraepithelial Neoplasia (CIN).
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
    The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
    The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
    Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
    Facilitates clinical trial assessment of the indication on a global, regional and country level
    Clinical Trials by G7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials
    Clinical Trials by E7 Countries: Proportion of Cervical Intraepithelial Neoplasia (CIN) to Women's Health Clinical Trials

New European Published Study Shows LuViva Detects 20% More Precancerous and Cancerous Cervical Disease than HPV Test

Biotechnology, Other Health, Health, General Health, Women, Oncology, Other Science, Medical devices, Research, Consumer, Science, Cancer, Infectious causes of cancer, Human papillomavirus infection, Positive and negative predictive values, Cervical screening, HPV-positive oropharyngeal cancer
Wednesday, July 28, 2021 - 2:00pm

In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.

Key Points: 
  • In addition, the confidence that a negative LuViva result truly indicated no significant disease (negative predictive value) was 90% for LuViva and 81% for HPV.
  • The confidence that a positive test result truly indicated presence of disease (positive predictive value) was about the same for both LuViva (35%) and HPV (37%).
  • According to new U.S. guidelines, women with this high a likelihood of cervical disease or higher need to either have tissue removed for a definitive diagnosis or consider immediate treatment.
  • The Companys first product is the LuViva Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care.

Fusion Pharmaceuticals Announces FDA Clearance of IND for FPI-1966, an Investigational Radiopharmaceutical for the Treatment of Head and Neck and Bladder Cancers Expressing FGFR3

Tyrosine kinase receptors, Clusters of differentiation, Infectious causes of cancer, Fibroblast growth factor receptor 3, Bladder cancer, Branches of biology, Cancer, Radiation therapy, Physical sciences, Radiation, Fibroblast growth factor receptor, Natural sciences
Wednesday, July 28, 2021 - 9:15pm

We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.

Key Points: 
  • We have an opportunity to selectively deliver alpha particles to these tumors and use precision radiation therapy as a new treatment paradigm.
  • While the currently approved pan-FGFR inhibitor for bladder cancer requires the presence of a specific mutation, our approach requires only over-expression of FGFR3.
  • The information that Fusion posts on this website could be deemed to be material information.
  • As a result, Fusion encourages investors, media and others interested to review the information that Fusion posts there on a regular basis.

Merck Announces Phase 3 KEYNOTE-355 Trial Met Primary Endpoint of Overall Survival (OS) in Patients with Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10)

General Health, Pharmaceutical, Health, Oncology, Clinical medicine, Cancer, Medicine, Orphan drugs, Breakthrough therapy, Antineoplastic drugs, Cancer immunotherapy, Infectious causes of cancer, Pembrolizumab, Merkel-cell carcinoma, Sorafenib, Hepatocellular carcinoma
Tuesday, July 27, 2021 - 11:45am

These new overall survival results confirm that KEYTRUDA in combination with chemotherapy represents an important treatment option for certain patients with metastatic TNBC.

Key Points: 
  • These new overall survival results confirm that KEYTRUDA in combination with chemotherapy represents an important treatment option for certain patients with metastatic TNBC.
  • The safety and effectiveness of KEYTRUDA in pediatric patients with MSI-H central nervous system cancers have not been established.
  • KEYTRUDA is indicated for the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.
  • KEYTRUDA is indicated for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC).

New CDC Guidelines Endorse Opt-Out Screening for Two of the Most Common Sexually Transmitted Infections (STIs), Recommend Nucleic Acid Testing for Mycoplasma Genitalium

Medical devices, Medical Supplies, Women, Infectious diseases, Biotechnology, AIDS, Health, Consumer, General Health, Sexually transmitted diseases and infections, Medical specialties, Clinical medicine, Infectious causes of cancer, Medicine, Mycoplasma, Synthetic biology, Mycoplasma genitalium, Urethritis, Cervicitis, Nucleic acid test, Protein M
Monday, July 26, 2021 - 1:02pm

For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.

Key Points: 
  • For the first time, CDC guidelines also defined specific populations (men with recurrent urethritis and women with recurrent cervicitis) to be tested for Mycoplasma genitalium and recommended nucleic-acid amplification testing (NAAT) for detection.
  • The 2015 CDC guidelines included M. genitalium as an emerging issue, but no FDA-cleared NAATs were available at that time11.
  • Hologic was first to market in 2019 with a NAAT for M. genitalium, and Hologics Aptima Mycoplasma genitalium Assay is specifically noted in the current guidelines1.
  • No FDA-cleared M. genitalium tests are available in the U.S. that detect antibiotic resistance, although Hologic is working to develop one.

Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Cancer, Carbonyl compounds, Health, Infectious causes of cancer, Asbestos, Occupational safety and health, Taxanes, Mesothelioma, Paclitaxel, Bladder cancer
Monday, July 26, 2021 - 9:00am

ONCOFID-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.

Key Points: 
  • ONCOFID-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
  • The onset of mesothelioma is closely related to exposure to asbestos, used as an insulator in many industries, from constructions to naval-aircraft and heavy industries.
  • ONCOFID-P is an innovative anti-cancer drug, a conjugate of paclitaxel (taxol) with hyaluronic acid (HA), resulting from the research of Fidia Farmaceutici.
  • Mesothelioma occurs in subjects exposed to this substance for work or proximity to sources of asbestos and after decades of exposure.

Fidia announces the FDA Orphan Drug designation for ONCOFID®-P for the treatment of malignant mesothelioma, the cancer caused by exposure to asbestos

Cancer, Clinical medicine, Health, Infectious causes of cancer, Taxanes, Cancer treatments, Antineoplastic drugs, Mesothelioma, Paclitaxel, Bladder cancer, Chemotherapy
Monday, July 26, 2021 - 9:00am

The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.

Key Points: 
  • The loco-regional administration makes ONCOFID-P an ideal anticancer drug in combination with existing treatments for patients with malignant mesothelioma.
  • ONCOFID-P is an anticancer drug in advanced clinical development for the loco-regional treatment of non-muscle invasive bladder cancer, on which it has already demonstrated potent efficacy and excellent tolerability.
  • The onset of mesothelioma is closely related to exposure to asbestos, used as an insulator in many industries, from constructions to naval-aircraft and heavy industries.
  • ONCOFID-P is an innovative anti-cancer drug, a conjugate of paclitaxel (taxol) with hyaluronic acid (HA), resulting from the research of Fidia Farmaceutici.

Abivax publishes a prospectus in the context of its capital increase and bonds offering

Hepatology, Abivax, Medical specialties, Infectious causes of cancer, Clinical medicine, Hepatocellular carcinoma, Medicine, Cancer
Saturday, July 24, 2021 - 2:11am

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnmo: ABVX).
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

Meridian Signs Definitive Agreement to Acquire Urea Breath Test for H. pylori from Otsuka America Pharmaceutical, Inc.

Medical specialties, Branches of biology, Clinical medicine, Breath tests, Helicobacter pylori, Infectious causes of cancer, Urea breath test, Gram-negative bacteria, Pathogenic bacteria, Urea, Helicobacter
Friday, July 23, 2021 - 2:20pm

With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.

Key Points: 
  • With this acquisition, Meridian will assume the customer relationships in North America to supply BreathTek, a urea breath test for the detection of Helicobacter pylori.
  • We look forward to supporting Otsukas customers with the gastrointestinal expertise and world class customer service Meridian is known for.
  • Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
  • Meridian is a fully integrated life science company that develops, manufactures, markets, and distributes a broad range of innovative diagnostic products.